Doctors start giving second round of shots to volunteers in Seattle COVID-19 vaccine trialhttps://www.usatoday.com/story/news/2020/04/22/second-round-shots-first-coronavirus-vaccine-test-start/3008506001/ The Seattle volunteers who got shots in the first trial of a possible coronavirus vaccine are now getting the second shot — an indicator the early trial is progressing well. While the doctors at Kaiser Permanente's Vaccine Treatment and Evaluation Unit in Seattle don’t know the results of the first round of tests, the fact that it has continued and that the second round of injections are now being given is good news, said Lisa Jackson, who is leading the study. “The trial hasn’t been stopped. We know from the study protocol that if adverse events had happened, the protocol would have required that,” she said. “Therefore we presume those things haven’t happened.” The volunteers are taking part in the first investigational vaccine study to fight coronavirus. The study launched on March 16. The vaccine, called mRNA-1273, was developed by scientists at the National Institute of Allergy and Infectious Diseases and at the Cambridge, Mass.-based biotechnology company Moderna, Inc..
The Seattle volunteers who got shots in the first trial of a possible coronavirus vaccine are now getting the second shot — an indicator the early trial is progressing well. While the doctors at Kaiser Permanente's Vaccine Treatment and Evaluation Unit in Seattle don’t know the results of the first round of tests, the fact that it has continued and that the second round of injections are now being given is good news, said Lisa Jackson, who is leading the study. “The trial hasn’t been stopped. We know from the study protocol that if adverse events had happened, the protocol would have required that,” she said. “Therefore we presume those things haven’t happened.” The volunteers are taking part in the first investigational vaccine study to fight coronavirus. The study launched on March 16. The vaccine, called mRNA-1273, was developed by scientists at the National Institute of Allergy and Infectious Diseases and at the Cambridge, Mass.-based biotechnology company Moderna, Inc..